Opinion|Videos|May 14, 2025
CSAI and INFUS-ON Study for Treatment of Parkinson Disease
Panelists discuss how the recently FDA-approved SPN-830 apomorphine infusion pump demonstrated significant efficacy in reducing off time and improving motor function in the INFUS-ON study, with physicians expressing optimistic views about both the US and European clinical trial results.
Advertisement
Episodes in this series
Video content above is prompted by the following:
SPN-830 FDA Approval and INFUS-ON Study
INFUS-ON Study Design:
- Phase 3, open-label study in patients with Parkinson disease with motor fluctuations
- Treatment duration of 12 months
- Primary end points: safety and tolerability
- Secondary end points: off time reduction, on time change, UPDRS scores
Efficacy Results:
- Significant reduction in daily off time (2.3 hours)
- Increase in on time without troublesome dyskinesias
- Improvement in motor function (UPDRS Part III scores)
- Benefits maintained throughout 12-month period
- Positive impact on quality-of-life measures
Safety Results:
- Most common adverse events (AEs): injection site reactions, nausea, dyskinesia
- Manageable safety profile with appropriate monitoring
- Low rate of serious AEs
- No significant cognitive or psychiatric adverse effects
Physician Impressions:
- Comparable efficacy results between TOLEDO and INFUS-ON studies
- Consistent safety profile across studies
- Meaningful clinical improvements in motor fluctuations
- Results generalizable to real-world clinical practice
- Need for dedicated support for infusion initiation and management
Advertisement
Related to this article
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
2
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
5